Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has announced that Bidi(R) Vapor has received a PMTA acceptance letter from the U.S. Food and Drug Administration (“FDA”). Kaival is the exclusive global distributor of Bidi Vapor LLC products. The PMTA letter marks an important milestone Bidi’s overall application is one step closer to meeting the FDA’s baseline criteria before moving into the substantive review, which is the final phase of the PMTA process. The PMTAa for Bidi Vapor now move on to the filing review phase. The acceptance letter includes all 11 flavors in the BidiStick line of products. Bidi Vapor and Kaival Brands have been involved in a complete overhaul in product packaging, branding and labeling to meet and even exceed the industry standards and FDA guidelines and requirements. “We look forward to working with FDA during the filing and substantive review of the PMTAs, and further demonstrating the uncompromising product quality Bidi Vapor brings, as evidenced by our recent distribution announcement with H.T. Hackney,” says Kaival Brands COO Eric Mosser in the press release. “Moving to the filing and, we anticipate, to the substantive review phase of the PMTA process is where our months of extensive data collection, investment and hard work assembling 285,000 pages of science-based evidence will pay off.”
To view the full press release, visit https://ibn.fm/ba7Zx
About Kaival Brands Innovations Group Inc.
Kaival Brands is focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Kaival’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. For more information, visit the company’s website at www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.